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Abstract
Gastric carcinoids (GCs) are classified as: type Ⅰ, 
related to hypergastrinemia due to chronic atrophic 
gastritis (CAG), type Ⅱ, associated with Zollinger-Ellison 
syndrome in multiple endocrine neoplasia type 1, and 
type Ⅲ, which is normogastrinemic. The management 
of type-Ⅰ gastric carcinoids (GC1s) is still debated, 
because of their relatively benign course. According to 
the European Neuroendocrine Tumor Society guidelines 
endoscopic resection is indicated whenever possible; 
however, it is not often feasible because of the presence 
of a multifocal disease, large lesions, submucosal 
invasion or, rarely, lymph node involvement. Therefore, 
somatostatin analogs (SSAs) have been proposed 
as treatment for GC1s in view of their antisecretive, 
antiproliferative and antiangiogenic effects. However, 
in view of the high cost of this therapy, its possible side 
effects and the relatively benign course of the disease, 
SSAs should be reserved to specific subsets of “high 
risk patients”, i.e. , those patients with multifocal or 
recurrent GCs. Indeed, it is reasonable that, after the 
development of a gastric neuroendocrine neoplasm in 
patients with a chronic predisposing condition (such as 
CAG), other enterochromaffin-like cells can undergo 
neoplastic proliferation, being chronically stimulated 
by hypergastrinemia. Therefore, definite indications to 
SSAs treatment should be established in order to avoid 
the undertreatment or overtreatment of GCs.
Key words: Neuroendocrine tumors; Atrophic gastritis; 
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Core tip: The management of type-Ⅰ gastric carcinoids 
is still debated because of their relatively benign course 
against the fact that they can have a heterogeneous 
extended to the deep submucosa or presenting 
lymph node involvement[13,14]. Moreover, the evolution 
to neuroendocrine carcinoma may occur in 3% of 
patients[15]. Nevertheless, local or distant metastases 
have been reported also in patients affected by GC1s 
with low proliferation index (< 2%), small size and 
exclusive intramucosal invasion[16-19]. In addition, GC1s 
frequently recur (5%-67% of cases after endoscopic 
treatment)[20,21], with a median recurrence-free time 
interval of 24 mo after endoscopic resection. Notably, 
recurrences are independent of polyp diameter, 
number of polyps or serum gastrin levels.
GC2s generally develop in patients with duodenal 
or pancreatic gastrinoma causing ZES syndrome 
in the context of a multiple endocrine neoplasia 
type Ⅰ (MEN-1)[22]. These are usually small multiple 
polyps (diameter of 1-2 cm ø), localized in the fundic 
mucosa, with a low or moderate proliferation grade, 
but may also exhibit angioinvasion, invasion of 
muscularis propria and metastases at regional lymph 
nodes or, less frequently, at distant sites. Unlike GC1s, 
GC2s are equally frequent in male and female patients. 
Their local excision is generally recommended, even 
in the presence of multiple lesions. In addition, in 
view of their antiproliferative effects, SSAs may be 
useful in those subgroups of patients presenting slowly 
progressive carcinoids. Tomassetti et al[23] observed 
GC2 regression in three patients with ZES/MEN-1 
after a long-term therapy with SSAs. However, 
the management of GC2s is complicated by the 
controversies regarding the treatment of gastrinoma 
in MEN-1. Indeed, the indication for extensive 
duodenal-pancreatic surgery in patients with MEN-1, 
who present pharmacologically controllable ZES and 
no other clinically symptomatic hormonal excess 
syndrome, remains debatable, also because SSAs play 
a role in reducing tumor growth[24].
GC3s are generally large (> 2 cm ø), solitary, 
ulcerated neoplasms, with infiltrative growth, elevated 
Ki-67 index and a higher risk of metastatic spreading 
when compared to GC1s and GC2s (metastatic rate 
of 50%-100%). GC3s occur mostly in men older 
than 50 years, presenting pain, anemia and weight 
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Table 1  Characteristics of gastric carcinoids according to the 
European Neuroendocrine Tumor Society guidelines[8]
GC1 GC2 GC3
Proportion among 
g-NEN
70%-80% 5%-6% 14%-25%
Grading NET G1 NET G1-G2 NEC G3
Associated conditions CAG Gastrinoma/
MEN-1
None
Serum gastrin values Elevated Elevated Normal
Metastases 2%-5% 10%-30% 50%-100%
Mortality rate 0% < 10% 25%-30%
GC 1, 2 and 3: Type Ⅰ, Ⅱ and Ⅲ gastric carcinoids; NENs: Neuro-
endocrine neoplasms; CAG: Chronic atrophic gastritis; MEN-1: Multiple 
endocrine neoplasia type Ⅰ.
unpredictable biological behavior. Even if in most 
cases their endoscopic treatment is effective, in some 
particular cases it may not be sufficient. The potential 
role of somatostatin analogs (SSAs) has been reported 
in several recent studies. However, neither a standard 
indication nor a specific schedule of treatment with 
defined dosage and duration have been adopted to 
date. Because of the high cost of SSAs, clear-cut 
indications for this therapy are required in order to 
avoid any overtreatment.
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INTRODUCTION
Gastric carcinoids - clinical features
Epidemiology: Gastric carcinoids (GCs) represent 
up to 23% of all digestive neuroendocrine neoplasms 
(NENs). Their annual incidence is of about 0.2/100000, 
with a marked increase in the last few decades, 
also owing to the expanding indications for upper 
gastrointestinal tract endoscopy (UGE) and improved 
immunohistological identification techniques[1-4]. Over 
the last 35 years a 10 to 15-fold increase has been 
reported in the United States[5] and in the United 
Kingdom[6] respectively. 
Modlin reported that the percentage of GCs among 
all gastric tumors has increased from 0.3% to 1.77%. 
Notably, the 5-year survival rate for GCs has risen 
from 51% to 63%[7].
Classification: GCs include three different types 
of gastric neuroendocrine tumors[8]: types Ⅰ (GC1s) 
and Ⅱ (GC2s) are related to hypergastrinemia, 
due to chronic atrophic autoimmune gastritis[9] and 
gastrinoma-related Zollinger-Ellison syndrome (ZES) 
respectively, while type Ⅲ (GC3s) are generally 
sporadic tumors, associated with normal gastrin levels 
and a worse prognosis[10] (Table 1).
GC1s account for 75%-80% of all GCs. They 
usually occur in women in their 50s and 70s and are 
usually asymptomatic and non-functioning, thus they 
are incidentally detected during UGE performed for 
other reasons, e.g., anemia or dyspepsia[11,12]. Most 
GC1 cases are polypoid with a median diameter of 5 
mm ø, generally confined to the mucosa-submucosa 
of the gastric fundus or body and, less frequently, 
antrum. They are usually well differentiated (i.e., with 
Ki-67 index < 2%), multiple in 65% of all cases and 
sometimes present as microcarcinoids, macroscopically 
undetectable at UGE. Noteworthy, 8%-23% of GC1s 
may metastasize to regional lymph nodes and seldom 
even to the liver, mainly when facing with lesions 
loss. Unlike GC1s and GC2s, GC3s may be associated 
with an atypical carcinoid syndrome, characterized 
by itching, bronchospasm and flushing, mediated by 
histamine released from enterochromaffin-like (ECL) 
cells. The management of GC3s is fairly clear and 
similar to that of gastric adenocarcinoma; it is based 
on surgery (partial or total gastrectomy with lymph 
node dissection) and chemotherapy if surgery is not 
feasible[8]. 
The treatment of metastatic liver disease includes 
hepatic resection, embolization of the hepatic artery, 
radiofrequency ablation and cryoablation.
Grading and staging: The histological classification 
of NENs includes grade (G) and differentiation. 
The grading system (Table 2) is based on the rate 
of proliferation, defined by the number of mitoses 
per 10 high-power microscopic fields or per 2 mm2 
(mitotic rate) and as the percentage of tumor cells 
positively immuno-labelling for the Ki-67 antigen (Ki-67 
index). Differentiation refers to the extent to which 
neoplastic cells resemble normal cells. Generally, well-
differentiated NENs are of low or intermediate grade, 
whereas poorly differentiated NENs are usually of high 
grade[25].
The tumor-node-metastasis (TNM) staging system 
is based on the size and/or extent (reach) of the 
primary tumor (T), whether cancer cells have spread 
to nearby (regional) lymph nodes (N), and whether 
any metastasis (M), or the spread of the cancer to 
other parts of the body, has occurred. According to 
the TNM staging, five stages can be considered: 0 for 
tumors in situ < 0.5 mm ø, Ⅰ for small NENs invading 
submucosa or lamina propria, Ⅱ for larger or more 
invasive neoplasms without metastases, Ⅲ for tumors 
invading surrounding structures or spreading to 
regional node metastases, and Ⅳ for NENs with distant 
metastases (Table 3)[26]. 
Type-i gastric carcinoids 
GC1s are neuroendocrine tumors of the gastric mucosa 
originating from ECL cells in response to chronic 
hypergastrinemia associated with chronic atrophic 
gastritis (CAG), either autoimmune or due to Helico­
bacter pylori infection. GC1s are the most frequent GCs, 
accounting for 70%-80% of all gastric NENs.
Pathogenesis: The ECL cells constitute the largest 
endocrine cell population of the gastric body and fundus 
mucosa; they express CCK-2 (gastrin) receptors, 
mediating cell growth and histamine secretion, and 
stimulate acid secretion from the adjacent parietal 
cells[27-29].
Due to the progressive destruction of gastric 
parietal cells, achlorhydria causes chronic hyper-
gastrinemia, which in turn is responsible for ECL cell 
hyperplasia and sometimes dysplasia, which over time 
may lead to ECL cell carcinoid development[30,31].
Among the factors influencing the trophic sensitivity 
of ECL cells to hypergastrinemia, the female gender is 
the most relevant one: the ECL cell hyperplasia is found 
more frequent in female than in male CAG patients. 
Furthermore, the decrease in ECL cells density with age 
increasing does not occur in women[32]. GCs associated 
with hypergastrinemia are more common in female 
subjects, whereas sporadic GCs, which develop through 
a gastrin-independent mechanism, occur mostly in 
males.
ECL cell hyperplasia may disappear when the 
hypergastrinemia is abolished. SSAs may be used 
to inhibit gastrin release and thus reduce the ECL 
cell hyperplasia[33]. Some morphometric studies 
have showed that antrectomy was responsible for a 
reduction of the ECL cell volume vs the total volume of 
endocrine cells, while octreotide reduced the volume of 
all endocrine cells[34].
In addition to chronic autoimmune atrophic 
gastritis, also the proton pump inhibitors, the use 
of which has been increasing worldwide, can induce 
gastric achlorhydria and consequent hypergastrinemia, 
even if the actual association with an increased 
risk of GCs has not been demonstrated yet[35]. 
Probably, hypergastrinemia does not represent the 
only risk factor predisposing to the development 
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Table 2  Grading of neuroendocrine neoplasms according to 
the World Health Organization 2010 classification[8]
Histological classification G1 (low 
grade)
G2 (intermediate 
grade)
G3 (high 
grade)
Mitotic rate (n/10 HPF) < 2 2–20 > 20
Ki-67 index < 3% 3%–20% > 20%
Table 3  Scoring staging system according to tumor-node-
metastasis[26]
T-primary tumor
   TX Primary tumor cannot be assessed
   T0 No evidence of primary tumor
   Tis In-situ tumor/dysplasia (< 0.5 mm)
   T1 Tumor invades lamina propria or submucosa and < 1 cm 
   T2 Tumor invades muscularis propria or subserosa or > 1 cm 
   T3 Tumor penetrates serosa 
   T4 Tumor penetrates serosa and/or invades adjacent structures
N-regional lymph nodes
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastasis 
   N1 Regional lymph node metastasis 
M-metastases
   MX Distant metastasis cannot be assessed 
   M0 No distant metastases
   M1 Distant metastases
Stage
   0 Tis N0 M0
   1 T1 N0 M0
   2A T2 N0 M0
   2B T3 N0 M0
   3A T4 N0 M0
   3B Any T N1 M0
   4 Any T Any N M1
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endoscopic eradication is not always feasible because 
carcinoids may be multifocal or submucosal. Many 
small studies have shown that the combination of 
endoscopic resection and surveillance of GC1s was 
a good treatment for lesions without local or distant 
spreading. Merola et al[21] reported a 100% survival 
rate and no metastases in endoscopically treated 
patients; however, the recurrence rate was up to 
68% after endoscopic resection. A lower recurrence 
rate (18% and 0.4%) is reported in recent Turkish[46] 
and Japanese studies[20] in which patients with GC1s 
were treated with EMR or ESD and followed up over 
a median of five years. Possible differences of the 
recurrence rates among these studies can depend on 
the difficulty to determine whether the lesions detected 
during follow-up endoscopies are true recurrences or 
simply small lesions missed at the initial endoscopy. 
Furthermore, more advanced endoscopic techniques, 
such as ESD and the routine use of chromoendoscopy, 
have been undertaken in Eastern countries, probably 
contributing to lower recurrence rates.
Currently, when dealing with the deep invasion 
of the gastric wall and detection of positive resection 
margins after endoscopic mucosal resection, local 
surgical tumor resection is generally performed. On the 
other hand, as this type of tumors are often multiple 
and recurrent, antral resection is recommended as it 
aims to avoid chronic gastrin stimulation of ECL cells 
and even if the long-term benefits of antrectomy 
remain uncertain[47,48]. Indeed, a further recurrence 
has been described in up to 20% of all cases and 
the surgical approach is more invasive and at higher 
risk of complications. However, in the case of disease 
progression or recurrence after local surgical resection, 
partial or total gastrectomy along with lymph node 
dissection should be carried out as suggested in the 
current guidelines[8].
Overall, the optimal treatment for GC1s remains 
controversial in view of their usually benign course, 
but also of their tendency to recur: a controlled study 
comparing the outcomes of endoscopic surveillance, 
endoscopic resection, surgical approach and SSAs 
treatment of GC1s is yet to be carried out. 
SSAs
Historical perspectives: The history of SSAs begins 
in 1973 when Brazeau and Guillemin discovered a 
GHRH antagonist, which they called somatostatin and 
which appeared to be widely distributed in the organs 
and nervous system[49] of animals and humans.
Noteworthy, native somatostatin plays an important 
regulatory role in neurotransmission and secretion, 
by preventing the release of the growth hormone, 
thyroid-stimulating hormone, gastrointestinal 
hormones, pancreatic enzymes and neuropeptides It 
is not suitable though for long-term clinical application 
due to its short half-life (< 3 min) and the impact of 
rebound hypersecretion. Therefore, synthetic drugs 
of gastric NENs, as not all GCs are associated with 
hypergastrinemia (see gastric carcinoid type Ⅲ) and 
not all the conditions associated with hypergastrinemia 
lead to neoplastic proliferation. This may also be 
promoted by genetic background, intragastric 
environmental changes related to achlorhydria 
and/or intramucosal modifications occurring in CAG, 
which have been implicated in the pathogenesis 
of gastric adenocarcinoma. Finally, factors such as 
prostanglandins and lymphokines, locally released 
during chronic inflammation, as in the case of CAG, 
may play a role in the pathogenesis of GCs[36,37].
Clinical and endoscopic features: These lesions, 
typically multicentric/multiple, small, usually with 
polypoid appearance (up to 78% according to 
Merola[21]) and localized in the oxyntic atrophic mucosa, 
are characterized by slow growth (low proliferative 
index Ki-67, i.e., G1 according to the World Health 
Organization classification) and a low tendency 
to local or distal invasion. Only larger lesions (> 1 
cm) are associated with lymph node or other organ 
spreading (in 3%-8% and 2% of cases, respectively), 
with a 5-year survival > 95%. These neoplasms only 
seldom have a functional syndrome, as in almost all 
cases they do not secrete specific hormones. Their 
detection is usually incidental or achieved during CAG 
follow-up. It is estimated that about 2.4%-5% of CAG 
patients develop GC1s in their lifetime, with an annual 
incidence of approximately 0.4% to 2.4%[9,11]. 
Since CAG is associated with chronic hyper-
gastrinemia, GC1s typically occur in the form of recurrent 
lesions. Moreover, even after endoscopic resection, up to 
67% of GC1s recur after a mean time of 24 mo, with a 
reported trend to evolve in less differentiated lesions.
Management of type-i gastric carcinoid - a clinical 
challenge
GC1s are usually treated conservatively. The European 
Neuroendocrine Tumor Society (ENETS) Consensus 
Guidelines have suggested that annual surveillance is 
sufficient in case of GC1s with a diameter < 10 mm 
ø[8]. This approach is supported by some reports[24,38-40] 
which suggest that careful endoscopic follow-up 
might represent a reasonable safe option in selected 
patients. However, further studies evaluating larger 
cohorts during a longer follow-up period are necessary 
in order to support this clinical behavior, as some cases 
of progressive malignant GC1s have already been 
reported[17-19,41].
Accordingly, the ENETS guidelines recommend 
endoscopic resection whenever possible, even in the 
presence of small carcinoids (diameter < 1 cm ø) 
and for up to 6 polyps not involving the muscularis 
propria[8]. Endoscopic mucosal resection (EMR) and 
submucosal dissection (ESD), characterized by a high 
rate of efficacy and a low risk of complications, have 
been suggested for treating GCs[42-46] but the complete 
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were developed with improved pharmacokinetic 
characteristics. SSAs have been used since 1980 to 
control the symptoms related to gastroenteropancreatic 
NENs, especially carcinoids and VIPomas, due to their 
characteristic of expressing somatostatin receptors 
(SSTR).
Long-acting SSAs have been used as a medical 
treatment of both functioning and non-functioning 
neuroendocrine tumors, due to the SSAs capability 
to inhibit hormone release and neoplastic growth by 
binding to specific high-affinity SSTR. Two different 
SSAs, octreotide and lanreotide, which principally bind 
to receptor subtypes 2 and 5, are clinically used with 
comparable effectiveness. Recently, pasireotide, a SSA 
with high affinity to all types of somatostatin receptors, 
has been introduced, even if its use is still restricted to 
those patients with partial/nil response to octreotide 
and lanreotide[50].
In a multicenter study comparing the treatment 
with lanreotide (30 mg i.m. every 10 d) vs octreotide 
(200 μg s.c. twice or thrice daily) in 33 patients with 
carcinoid syndrome, O’Toole et al[51] did not evidence 
any significant differences with regard to symptom 
control. Again, both these analogs have been reported 
to have an antiproliferative effect in vitro[52,53]. Data 
from uncontrolled prospective and retrospective 
clinical series[54-56] showed tumor shrinkage and 
disappearance in response to either short-acting 
SSAs alone or when combined with interferon-α. 
Further trials have reported tumor stabilization in up 
to 50% of patients, but without complete regression. 
More recently, two randomized double-blind placebo-
controlled prospective studies[57,58] have clearly 
supported the antiproliferative effects of SSAs with 
a prolonged progression-free-survival in patients 
affected by enteropancreatic neuroendocrine tumors 
and treated with octreotide LAR (long-acting release) 
and lanreotide. However, there is need for additional 
studies, including patients with a primary tumor 
outside the midgut, in order to demonstrate the 
antiproliferative effects of octreotide. Again, further 
controlled trials in larger cohorts of patients are 
strongly required in order to identify the predictive 
factors of response and to confirm whether such a 
response may positively influence the patients’ survival 
rate.
Benefits of SSAs therapy: The antineoplastic effects 
of somatostatin and SSAs are both direct and indirect, 
the former depending on the direct binding to tumor 
cells, the latter ones mediated through the inhibition 
of growth factors, angiogenesis and the immune 
system. The anti-tumour effect of SSAs may include 
both cytostatic (growth arrest) and cytotoxic (pro-
apoptotic) mechanisms[59-62]. SSAs may also inhibit 
the insulin-like growth factor-Ⅰ secretion, thought to 
be involved in recurrence, growth and aggressiveness 
of some endocrine and non-endocrine tumors[63]. In a 
systematic analysis of data from 62 published studies 
about antiproliferative effects of SSAs[64], tumor growth 
stabilization was observed for a period of 8-16 mo in 
about 50% of the patients, and tumor regression in 
about 10%-20% of patients.
Unfortunately, tachyphylaxis can develop after 
months or years on treatment, probably due to the 
development of resistant cell clones within the tumor, 
whereas it does not seem related to any down-
regulation of the number of somatostatin receptors on 
the cell surface. 
Another relevant antiproliferative effect of SSAs 
is based on their capability to inhibit the production 
and secretion of many angiogenic factors, thereby 
reducing the tumor growth rate[65]. Therefore, SSAs 
may suppress tumor growth either directly, through 
their effect on SSTR expressing cells, or indirectly, via 
the inhibition of angiogenic factors, such as VEGF[66].
Finally, SSAs have an antisecretive role, as 
supported by a study by Fykse et al[67] in which five 
patients with hypergastrinemia and GCs were every 
month treated with octreotide LAR over one year with 
the consequent significant reduction in tumor burden, 
ECL cell grade of hyperplasia and the normalization of 
circulating chromogranin A levels. A further study[23] 
reported a significant reduction in gastrin levels and 
tumor regression in three patients suffering from 
Zollinger-Ellison syndrome and treated with lanreotide 
or octreotide for one year. Despite the small number of 
patients included in these studies, the results suggest 
that SSAs both inhibit gastrin secretion and growth of 
these tumors.
Side effects of SSAs therapy: Generally, SSAs are 
safe, easy to use and well tolerated with infrequent 
mild side effects, the most common being abdominal 
discomfort, bloating, diarrhea (related to the inhibition 
of pancreatic enzymes) usually self-limiting after 
the first few months of therapy. The development of 
cholestasis is reported in up to 60% of patients and 
can be partially prevented by orally administered 
ursodeoxycholic acid. Impaired glucose tolerance and 
bradycardia have also been occasionally reported[68].
Somatostatin analogs … for many gastric carcinoids
Endoscopic resection has proved to represent a 
safe effective treatment for GC1s as it is associated 
with a 100% survival rate, even if recurrences have 
been described with a frequency of up to 67% of 
all patients endoscopically treated[21]. Indeed, GC1s 
are frequently multiple and can present submucosal 
invasion; in addition, they are sometimes undetectable 
at UGE, as they present as microcarcinoids. Therefore, 
the endoscopic approach is not always effective or 
adequate and other treatment options are needed 
for some subgroups of “high risk” patients, i.e., those 
with a multifocal or recurrent disease. Moreover GC1s 
can be considered a complication of another disorder 
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that involves the entire gastric mucosa, so that a 
locoregional treatment may not be appropriate and a 
systemic therapy is thus a more pertinent approach.
SSAs have been proposed as a potential treatment 
in view of their antiproliferative, antisecretive and 
antiangiogenic effects, although they are not currently 
recommended according to both the ENETS[8] and 
NANETS guidelines[69] for type-1 GCs.
Of interest, Ferraro et al[70] observed that octreotide, 
given daily over six months, decreased fasting gastrin 
levels and ECL proliferation in patients with CAG and 
hypergastrinemia. Bakke et al[71] have reported a direct 
antiproliferative effect of octreotide on rat ECL cells. 
SSAs have also been occasionally used in tertiary 
referral centres to treat single or multiple GC1s with 
diameter < 1 cm ø and low proliferative index[72]. 
When administered in a continuous way, SSAs have 
contributed to the reduction in number and size 
of GC1s and the suppression of circulating gastrin 
levels, by inhibiting gastrin release from antral G 
cells. However, a series by Jianu et al[73] has reported 
GC1 size increase and early recurrence after the SSA 
withdrawal in patients followed up over a median of 
5 years from therapy discontinuation. One should 
consider though that such findings have not been 
confirmed by other studies.
Reasonably, after the development of a neuro-
endocrine neoplasm, other ECL cells can develop 
neoplastic proliferation in similar conditions (e.g., 
chronic hypergastrinemia). Therefore, patients with 
recurrent GC1s should be considered at higher risk of 
developing other recurrences.
Somatostatin analogs … not for all 
Not all GC1 patients are to be treated with SSAs 
on the consideration that such a therapy comes 
with high costs attached and the 5-year survival 
rate of GC1 patients when regularly followed up 
with endoscopy remains good[74]. Accordingly, SSAs 
are better reserved to specific subsets of patients, 
such as those with recurrent or multifocal GC1s. 
Actually, no clear guidelines are currently available 
for patients presenting GC1 recurrence after repeated 
endoscopic resection. For these patients antrectomy 
has been proposed in spite of its invasiveness and 
possibly related complications[75]. Furthermore, 
some morphometric studies have demonstrated that 
octreotide reduced the overall endocrine cell volume[76], 
while antrectomy decreased only the volume of ECL 
cells.
A further treatment option can be that of multiple 
endoscopic resections; however, in the context of CAG, 
gastric mucosa is chronically and diffusely altered and 
GC1s are often multifocal, extended to submucosa 
and sometimes macroscopically undetectable, making 
endoscopic resection not always feasible and radical. 
In those countries where advanced endoscopic 
techniques are in place, management by endoscopy 
can also apply to multifocal GCs and GCs involving the 
submucosal layer and hence endoscopic resection is 
preferred as the first-line therapy. The far larger use of 
standard polipectomies instead of the more effective 
“en bloc” resection and ESD might account for the still 
high recurrence rates observed in some series[21].
Given the above considerations, we have recently 
reported on a series of CAG patients with recurrent 
GC1s, treated with SSAs until carcinoid disappearance 
and suppression of circulating gastrin values. For 
such patients SSAs have represented an efficient 
therapeutic option (Massironi et al submitted). As 
already reported, SSAs can exert an antiproliferative 
effect on neoplastic ECL-cells as well as other 
hyperplastic or dysplastic ECL-cells, which frequently 
accompanied GC1s, thus reducing the risk of further 
development[77]. Moreover, several studies[19] have 
reported that SSAs might significantly suppress 
intestinal metaplasia, which may be present in patients 
with chronic atrophic gastritis and may represent a risk 
factor for gastric adenocarcinoma[78,79].
Another pharmacological therapeutic option is 
represented in the near future by netazepide, an orally 
administered highly selective active gastrin/CCK-2 
receptor antagonist, recently described as an effective 
treatment in animal models of ECL-cell tumours 
induced by hypergastrinemia[80]. Its use over a 12-wk 
period in a recent non-randomized trial was associated 
with a significant reduction in both the number of GC1s 
and the size of the largest tumour, of about 30%, and 
with the normalization of CgA levels, but not of gastrin 
values[81]. Nevertheless, randomized controlled trials 
involving longer-term treatment and larger cohorts of 
patients, are required to confirm these results.
CONCLUSION
Approval is still to come for specific indications, schedule 
and duration of therapy to avoid the undertreatment 
or overtreatment of recurrent GC1s. The duration 
of a SSA-based therapy may be guided by both the 
regression of GC and the suppression of gastrin levels. 
Finally, the comparison between new therapies, such 
as gastrin receptor antagonists and antibodies against 
progastrin-releasing peptides, and the traditional 
ones, such as the endoscopic or surgical approaches, 
can be useful in order to identify the most effective 
management approach.
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